Q3 2024 Treace Medical Concepts Inc Earnings Call Transcript
Key Points
- Treace Medical Concepts Inc (TMCI) reported third-quarter revenue of $45.1 million, representing an 11% growth over the same period in 2023.
- The company announced the limited market release of the Nanoplasty 3D MIS System, marking its entry into the large metatarsal osteotomy market.
- TMCI's gross margin remained strong at 80.1% for the third quarter of 2024.
- The company is expanding its product portfolio with new technologies like Adductoplasty and SpeedPlate, which have seen increased adoption.
- TMCI revised its full-year 2024 revenue guidance upwards to $204 million to $211 million, reflecting a 9% to 13% increase over 2023 revenue.
- TMCI reported a net loss of $15.4 million for the third quarter, although this was an improvement from the $17.5 million loss in the same period of 2023.
- Operating expenses increased to $51.3 million in the third quarter of 2024, up from $50.6 million in the same period of 2023.
- The company is facing competitive pressures and has filed a patent infringement and unfair competition lawsuit against Stryker Corporation.
- There are uncertainties regarding the adoption and market reception of new products like the Nanoplasty 3D MIS System, which currently lacks clinical data.
- TMCI's guidance for the fourth quarter implies a step down in growth, with potential impacts from factors like hurricane disruptions and IV bag rationing.
Good day. And thank you for standing by. Welcome to the Treace Medical Concepts. Third quarter, 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today. Vivian Cervantes, Investor Relations, Gilmartin Group. Please go ahead.
Thank you, Operator. Good afternoon, everyone and welcome to our third quarter, 2024 earnings conference call participating from the company today will be John Treace, Chief Executive Officer; and Mark Hair, Chief Financial Officer.
During the call, John will offer commentary on our commercial activities followed by mark for a review for third quarter financial results released after market closed today, we will host a question and answer session following our prepared remarks. Our press release can be found on the investor relations section of our website at investors.treace.com. This call is being recorded and will be archived in the investors section
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
